MedElevator
Войти в исследования Future oncology (London, England) · 2025
A multicenter Phase II study of mFOLFOX6 plus nivolumab for gastric cancer with severe peritoneal metastases: WJOG16322G.
Клиническое исследование II фазыСтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wakabayashi Munehiro, Masuishi Toshiki, Ogata Takatsugu, Hanamura Fumiyasu, Furuta Mitsuhiro, Yamamoto Yoshiyuki, Kawakami Kentaro, Hirano Hidekazu, Kito Yosuke, Izawa Naoki, Takahashi Naoki, Matsumoto Toshihiko, Kawakami Hisato, Ando Takayuki, Minashi Keiko, Kudo Chiho, Yoshimura Kenichi, Muro Kei
Аннотация
Advanced gastric cancer (AGC) patients with severe peritoneal metastases (SPM), characterized by massive ascites and/or inadequate oral intake, have a poor prognosis with the median overall survival of around 7 months, even when treated with fluorouracil/l-leucovorin plus oxaliplatin (mFOLFOX6), despite being a treatment options for these patients demonstrated in the WJOG10517G study. However, these patients were excluded from pivotal Phase III trials, including the CheckMate 649 study, which demonstrated the benefit of adding nivolumab to mFOLFOX6, due to tumor-related complications. Given the lack of data on the efficacy and safety of combining nivolumab with mFOLFOX6 for AGC patients with SPM, we initiated a Phase II study to evaluate this combination. The primary endpoint was the 1-year survival rate.Clinical trial registration: Japan Registry of Clinical Trials (jRCTs) 041220164.